Skip to Content

MiMedx Group Inc MDXG

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from human amniotic membrane and birth tissues and human skin and bone. Its products are primarily targeted toward the wound-care, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. It also sells OrthoFlo, an allograft derived from amniotic fluid. In addition, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Contact
1775 West Oak Commons Court NE
Marietta, GA, 30062
T +1 770 651-9100
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Distressed
Employees 696